Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13406284 | 0.91 | HSD17B10 (0.83) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13405879 | 0.89 | TP53 (0.86) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13405944 | 0.89 | HSD17B10 (0.80) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13406197 | 0.88 | HSD17B10 (0.78) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13406063 | 0.88 | HSD17B10 (0.78) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13406216 | 0.87 | HSD17B10 (0.77) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13406213 | 0.87 | HSD17B10 (0.76) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13405890 | 0.87 | LMNA (1.00) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL14332418 | 0.87 | ALDH1A1 (0.84) | HSD17B10CTSSLMNATP53PKM | |
| SCHEMBL13406062 | 0.87 | CTSS (1.00) | HSD17B10CTSSLMNATP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705031-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309716-B2 | Benzimidazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306129-A1 | BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS | KCNJ11, KCNJ1, KCNJ2 | HSD17B10 3940/4885CTSS 3275/4885LMNA 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.